

REMARKS

Upon entry of the above preliminary amendment, claims 1-5 and 7-12 will be pending. Applicants canceled claim 6. Applicants have amended the claims to conform to US Patent practice. New claims 11-12 find support in the original claims and specification.

Applicants have amended the specification to correct syntax and typographical errors.

Applicants respectfully submit that no new matter issues have been raised.

Applicants request that the sequence listing in the computer readable form (CRF) filed in the parent application, Application No. 09/674,866, filed on June 13, 2002, be used as the CRF in this Divisional Application. A paper copy has been submitted with the instant application.

Conclusion


Applicants submit that the present claims define patentable subject matter and are in condition for allowance.

Should the Examiner believe that a conference would be helpful in advancing the prosecution of this application, he is invited to telephone Applicants' Attorney at the number below.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334 for any additional

fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly,
extension of time fees.

Respectfully submitted,



Mark W. Milstead
Attorney for Applicants
Registration No. 45,825

Attorney Docket NO. I/98376 US D1

Akzo Nobel Pharma Patent Department
Intervet Inc.
405 State Street
Millsboro, DE 19966
Tel: (302) 934-4395
Fax: (301) 934-4305

MWM